[1]
|
H. Chen, R. S. Sippel, M. S. O’Dorisio, A. I. Vinik, R. V. Lloyd and K. Pacak, “North American Neuroendocrine Tumor Society (NANETS). The North American Neuroendocrine Tumor Society Consensus Guideline for the Diagnosis and Management of Neuroendocrine Tumors: Pheochromocytoma, Paraganglioma, and Medullary Thyroid Cancer,” Pancreas, Vol. 39, 2010, pp. 775-783.
doi:10.1097/MPA.0b013e3181ebb4f0
|
[2]
|
K. Pacak, G. Eisenhofer, H. Ahlman, S. R. Bornstein, A. P. Gimenez-Roqueplo, A. B. Grossman, N. Kimura, M. Mannelli, A. M. McNicol and A. S. Tischler, “International Symposium on Pheochromocytoma. Pheochromocytoma: Recommendations for Clinical Practice from the First International Symposium. October 2005,” Nature Clinical Practice Endocrinology & Metabolism, Vol. 3, 2007, pp. 92-102. doi:10.1038/ncpendmet0396
|
[3]
|
W. F. Young, Williams Textbook of Endocrinology, Saunders/Elsevier, Philadelphia, 2008.
|
[4]
|
J. W. Lenders, G. Eisenhofer, M. Mannelli and K. Pacak, “Phaeochromocytoma,” Lancet, Vol. 20-26, No. 366, 2005, pp. 665-675. doi:10.1016/S0140-6736(05)67139-5
|
[5]
|
S. S. Bajwa and S. K. Bajwa, “Implications and Considerations during Pheochromocytoma Resection: A Challenge to the Anesthesiologist,” Indian Journal of Endocrinology & Metabolism, Vol. 15, No. S4, 2011, pp. S337-S344.
doi:10.4103/2230-8210.86977
|
[6]
|
G. Eisenhofer, G. Rivers, A. L. Rosas, Z. Quezado, W. M. Manger and K. Pacak, “Adverse Drug Reactions in Patients with Phaeochromocytoma: Incidence, Prevention and Management,” Drug Safety, Vol. 30, 2007, pp. 1031-1062.
doi:10.2165/00002018-200730110-00004
|
[7]
|
M. A. Kinney, B. J. Narr and M. A. Warner, “Perioperative Management of Pheochromocytoma,” Journal of Cardiothoracic and Vascular Anesthesia, Vol. 16, 2002, pp. 359-369. doi:10.1053/jcan.2002.124150
|
[8]
|
K. Pacak, “Preoperative Management of the Pheochromocytoma Patient,” Indian Journal of Endocrinology & Metabolism, Vol. 92, 2007, pp. 4069-4079.
doi:10.1210/jc.2007-1720
|
[9]
|
C. Lentschener, S. Gaujoux, A. Tesniere and B. Dousset, “Point of Controversy: Perioperative Care of Patients Undergoing Pheochromocytoma Removal-Time for a Reappraisal?” European Journal of Endocrinology, Vol. 165, 2011, pp. 365-373. doi:10.1530/EJE-11-0162
|
[10]
|
R. T. Wall, “Stoelting’s Anesthesia and Co-Existing Disease,” Saunders/Elsevier, Philadelphia, 2008.
doi:10.1016/B978-1-4160-3998-3.10016-8
|
[11]
|
I. Jugovac, M. Antapli and S. Markan, “Anesthesia and Pheochromocytoma,” International Anesthesiology Clinics, Vol. 49, 2011, pp. 57-61.
doi:10.1097/AIA.0b013e3181ff4db0
|
[12]
|
T. C. Westfall and D. P. Westfall, “The Pharmacologycal Basis of Therapeutics,” McGraw Hill, New York, 2011.
|
[13]
|
H. Bruynzeel, R. A. Feelders, T. H. Groenland, A. H. van den Meiracker, C. H. van Eijck, J. F. Lange, W. W. de Herder and G. Kazemier, “Risk Factors for Hemodynamic Instability during Surgery for Pheochromocytoma,” Journal of Clinical Endocrinology & Metabolism, Vol. 95, 2010, pp. 678-685. doi:10.1210/jc.2009-1051
|
[14]
|
A. Nizamoglu, Z. Salihoglu and M. Bolayrl, “Effects of Epidural-and-General Anesthesia Combined versus General Anesthesia during Laparoscopic Adrenalectomy,” Surgical Laparoscopy Endoscopy & Percutaneous Techniques, Vol. 21, 2011, pp. 372-379.
doi:10.1097/SLE.0b013e31822dd5e1
|
[15]
|
T. Isosu, S. Obara, S. Ohashi, A. Hosono, Y. Nakano, T. Imaizumi, M. Mogami, H. Iida and M. Murakawa, “Examination of the Usefulness of Non-Invasive Stroke Volume Variation Monitoring for Adjusting Fluid Supplementation during Laparoscopic Adrenalectomy in Patients with Pheochromocytoma,” Fukushima Journal of Medical Science, Vol. 58, 2012, pp. 78-81.
doi:10.5387/fms.58.78
|
[16]
|
R. Domia and H. Sulaa, “Pheochromocytoma, the Challenge to Anesthesiologists,” Journal of Endocrinology & Metabolism, Vol. 1, 2011, pp. 97-100.
|
[17]
|
M. A. Kinney, M. E. Warner, J. A. van Heerden, T. T. Horlocker, W. F. Young Jr., D. R. Schroeder, P. M. Maxson and M. A. Warner, “Perianesthetic Risks and Outcomes of Pheochromocytoma and Paraganglioma Resection,” Anesthesia & Analgesia, Vol. 91, 2000, pp. 1118-1123.
|
[18]
|
M. F. James and L. Cronjé, “Pheochromocytoma Crisis: The Use of Magnesium Sulfate,” Anesthesia & Analgesia, Vol. 99, 2004, pp. 680-686.
doi:10.1213/01.ANE.0000133136.01381.52
|
[19]
|
S. Herroeder, M. E. Schönherr, S. G. De Hert and M. W. Hollmann, “Magnesium—Essentials for Anesthesiologists,” Anesthesiology, Vol. 114, 2011, pp. 971-993.
doi:10.1097/ALN.0b013e318210483d
|
[20]
|
M. S. Lord and J. G. Augoustides, “Perioperative Management of Pheochromocytoma: Focus on Magnesium, Clevidipine, and Vasopressin,” Journal of Cardiothoracic and Vascular Anesthesia, Vol. 26, 2012, pp. 526-531.
doi:10.1053/j.jvca.2012.01.002
|
[21]
|
A. N. Van der Horst-Schrivers, M. N. Kerstens and B. H. Wolffenbuttel, “Preoperative Pharmacological Management of Phaeochromocytoma,” Netherlands Journal of Medicine, Vol. 64, 2006, pp. 290-295.
|